Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry

The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding comp...

Full description

Bibliographic Details
Main Authors: Jan Beyer-Westendorf, Sandra Marten, Luise Tittl, Christiane Naue, Martin Bornhäuser
Format: Article
Language:English
Published: Georg Thieme Verlag KG 2021-04-01
Series:TH Open
Subjects:
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675
id doaj-2282bef639334a1e89e4e3281edb7a42
record_format Article
spelling doaj-2282bef639334a1e89e4e3281edb7a422021-05-04T22:57:57ZengGeorg Thieme Verlag KGTH Open2512-94652021-04-010502e143e15110.1055/s-0041-1728675Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC RegistryJan Beyer-Westendorf0Sandra Marten1Luise Tittl2Christiane Naue3Martin Bornhäuser4Thrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThrombosis Research Unit, Division Hematology, Department of Medicine I, University Hospital “Carl Gustav Carus” Dresden, Dresden, GermanyThe effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding complications during apixaban treatment of VTE patients. For this analysis, we only included patients with acute VTE who started apixaban within 14 days after diagnosis and who were enrolled within these 14 days. Patient characteristics, treatment persistence, and clinical outcomes were assessed. Between August 1st, 2014 and October 31, 2018, 352 patients with apixaban treatment for acute VTE were enrolled. During treatment (median exposure 13.7 ± 9.8 months; median follow-up 21.7 ± 6.1 months) rates of recurrent VTE and International Society on Thrombosis and Haemostasis major bleeding were 1.3/100 pt.years (95% confidence interval or CI 0.4–3.0) and 1.5/100 pt.years (0.6–3.3), respectively. At 6 months. 68.6% of patients were still taking apixaban, 23.9% had a scheduled end of treatment, 6.3% were switched to other anticoagulants, and the remaining 2.3% had unplanned complete discontinuation of anticoagulation. Of the 188 patients stopping apixaban, 12 (6.4%) experienced a recurrent VTE (six pulmonary embolisms ± deep vein thrombosis, six deep vein thrombosis; mean time between stopping anticoagulation and VTE recurrence 5.2 ± 4.1 months [range 14–417 days]). Our findings suggest that, in daily care, apixaban demonstrated high effectiveness, safety, and persistence in the treatment of acute VTE with low rates of unplanned discontinuation.http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675anticoagulationbleedingpersistenceapixabanvenous thromboembolism
collection DOAJ
language English
format Article
sources DOAJ
author Jan Beyer-Westendorf
Sandra Marten
Luise Tittl
Christiane Naue
Martin Bornhäuser
spellingShingle Jan Beyer-Westendorf
Sandra Marten
Luise Tittl
Christiane Naue
Martin Bornhäuser
Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
TH Open
anticoagulation
bleeding
persistence
apixaban
venous thromboembolism
author_facet Jan Beyer-Westendorf
Sandra Marten
Luise Tittl
Christiane Naue
Martin Bornhäuser
author_sort Jan Beyer-Westendorf
title Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
title_short Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
title_full Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
title_fullStr Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
title_full_unstemmed Venous Thromboembolism Therapy with Apixaban in Daily Care Patients: Results from the Dresden NOAC Registry
title_sort venous thromboembolism therapy with apixaban in daily care patients: results from the dresden noac registry
publisher Georg Thieme Verlag KG
series TH Open
issn 2512-9465
publishDate 2021-04-01
description The effectiveness and safety of venous thromboembolism (VTE) treatment with apixaban, demonstrated in phase III trials, need to be confirmed in daily care. Using data from the prospective, noninterventional cross-indication Dresden NOAC Registry we evaluated rates of VTE recurrence and bleeding complications during apixaban treatment of VTE patients. For this analysis, we only included patients with acute VTE who started apixaban within 14 days after diagnosis and who were enrolled within these 14 days. Patient characteristics, treatment persistence, and clinical outcomes were assessed. Between August 1st, 2014 and October 31, 2018, 352 patients with apixaban treatment for acute VTE were enrolled. During treatment (median exposure 13.7 ± 9.8 months; median follow-up 21.7 ± 6.1 months) rates of recurrent VTE and International Society on Thrombosis and Haemostasis major bleeding were 1.3/100 pt.years (95% confidence interval or CI 0.4–3.0) and 1.5/100 pt.years (0.6–3.3), respectively. At 6 months. 68.6% of patients were still taking apixaban, 23.9% had a scheduled end of treatment, 6.3% were switched to other anticoagulants, and the remaining 2.3% had unplanned complete discontinuation of anticoagulation. Of the 188 patients stopping apixaban, 12 (6.4%) experienced a recurrent VTE (six pulmonary embolisms ± deep vein thrombosis, six deep vein thrombosis; mean time between stopping anticoagulation and VTE recurrence 5.2 ± 4.1 months [range 14–417 days]). Our findings suggest that, in daily care, apixaban demonstrated high effectiveness, safety, and persistence in the treatment of acute VTE with low rates of unplanned discontinuation.
topic anticoagulation
bleeding
persistence
apixaban
venous thromboembolism
url http://www.thieme-connect.de/DOI/DOI?10.1055/s-0041-1728675
work_keys_str_mv AT janbeyerwestendorf venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry
AT sandramarten venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry
AT luisetittl venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry
AT christianenaue venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry
AT martinbornhauser venousthromboembolismtherapywithapixabanindailycarepatientsresultsfromthedresdennoacregistry
_version_ 1721477180222865408